YU41100A - N-acil derivati cikličnih amina - Google Patents
N-acil derivati cikličnih aminaInfo
- Publication number
- YU41100A YU41100A YU41100A YU41100A YU41100A YU 41100 A YU41100 A YU 41100A YU 41100 A YU41100 A YU 41100A YU 41100 A YU41100 A YU 41100A YU 41100 A YU41100 A YU 41100A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- diseases
- hydrogen
- represent
- optionally substituted
- lower alkyl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 102000017925 CHRM3 Human genes 0.000 abstract 1
- 101150060249 CHRM3 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 208000012931 Urologic disease Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Fats And Perfumes (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Pronalazak se odnosi na jedinjenja prikazana opstom formulom [I] u kojoj Ar oznacava aril-grupu iil heteroaril-grupu koja moze da bude supstituisana atomom halogena, nizom alkil-grupom i nizom alkoksi-grupom; R1 oznacava cikloalkil-grupu sa 3 do 6 atoma ugljenika koja moze da bude supstituisana atomom fluora; R2 i R4 oznacavaju atom vodonika, grupe prikazane formulom -(A1)m-NH-B i slicno; R3 i R5 oznacavaju atom vodonika, alifaticnu ugljovodonicnu grupu sa 1 do 6 atoma ugljenika ili slicno, koja moze da bude supstituisana sa jednom ili vise nizih alkil-grupa; n oznacava 0 ili 1; a X oznacava atom kiseonika ili sumpora. Jedinjenja iz ovog pronalaska, posto ne samo da ispoljavaju selektivnu antagonisticku aktivnost prema muskarinskim M3 receptorima, vec imaju i izuzetnu oralnu aktivnost, trajsnot dejstva i farmakokinetiku, veoma su korisna kao bezbedna i efikasna sredstva protiv respiratornih, urinarnih i digestivnih oboljenja, pri cemu ne ispolajvaju znacajne sporedne efekte.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3806398 | 1998-02-04 | ||
| JP22872698 | 1998-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU41100A true YU41100A (sh) | 2002-06-19 |
Family
ID=26377245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU41100A YU41100A (sh) | 1998-02-04 | 1999-02-03 | N-acil derivati cikličnih amina |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6140333A (sh) |
| EP (1) | EP1061076B1 (sh) |
| JP (1) | JP3613179B2 (sh) |
| KR (1) | KR20010040693A (sh) |
| CN (1) | CN1290251A (sh) |
| AR (1) | AR015512A1 (sh) |
| AT (1) | ATE284389T1 (sh) |
| AU (1) | AU745995B2 (sh) |
| BG (1) | BG104663A (sh) |
| BR (1) | BR9908351A (sh) |
| CA (1) | CA2317444C (sh) |
| DE (1) | DE69922494T2 (sh) |
| EE (1) | EE200000458A (sh) |
| ES (1) | ES2235458T3 (sh) |
| HR (1) | HRP20000495B1 (sh) |
| HU (1) | HUP0102404A2 (sh) |
| IL (1) | IL137166A0 (sh) |
| IS (1) | IS5580A (sh) |
| PE (1) | PE20000263A1 (sh) |
| PL (1) | PL342735A1 (sh) |
| SK (1) | SK11402000A3 (sh) |
| TR (1) | TR200002241T2 (sh) |
| WO (1) | WO1999040070A1 (sh) |
| YU (1) | YU41100A (sh) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1185400A (en) * | 1998-11-20 | 2000-06-13 | Banyu Pharmaceutical Co., Ltd. | 1-acylazetidine derivatives |
| US6476046B1 (en) * | 2000-12-04 | 2002-11-05 | Sepracor, Inc. | Diazabicyclo[4.3.0]nonanes, and methods of use thereof |
| MXPA03008109A (es) * | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| SE0303090D0 (sv) | 2003-11-20 | 2003-11-20 | Astrazeneca Ab | Novel compounds |
| SE0303541D0 (sv) | 2003-12-22 | 2003-12-22 | Astrazeneca Ab | New compounds |
| CN1980929A (zh) * | 2004-02-24 | 2007-06-13 | 比奥阿克松医疗技术股份有限公司 | 4－取代哌啶衍生物 |
| EP2146957B1 (en) | 2007-04-24 | 2013-06-12 | Theravance, Inc. | Quaternary ammonium compounds useful as muscarinic receptor antagonists |
| CN101796026B (zh) | 2007-09-07 | 2013-10-23 | 施万制药 | 可用作毒蕈碱受体拮抗剂的含胍化合物 |
| US8017617B2 (en) * | 2007-12-14 | 2011-09-13 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| JP2011513421A (ja) * | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| US8278313B2 (en) | 2008-03-11 | 2012-10-02 | Abbott Laboratories | Macrocyclic spiro pyrimidine derivatives |
| US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
| US8796297B2 (en) | 2009-06-30 | 2014-08-05 | Abbvie Inc. | 4-substituted-2-amino-pyrimidine derivatives |
| ES2618703T3 (es) * | 2012-06-13 | 2017-06-22 | F. Hoffmann-La Roche Ag | Nuevos compuestos diazaspirocicloalcano y azaspirocicloalcano |
| CN104684915B (zh) | 2012-09-25 | 2017-10-31 | 霍夫曼-拉罗奇有限公司 | 新型双环衍生物 |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US9580431B2 (en) | 2013-03-13 | 2017-02-28 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| KR20160087900A (ko) | 2013-11-26 | 2016-07-22 | 에프. 호프만-라 로슈 아게 | 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일 |
| CN106029667B (zh) | 2014-03-26 | 2019-08-23 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物 |
| AU2015238537B2 (en) | 2014-03-26 | 2019-08-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| US9687483B2 (en) | 2015-01-26 | 2017-06-27 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors |
| US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
| RU2725138C2 (ru) | 2015-09-24 | 2020-06-30 | Ф. Хоффманн-Ля Рош Аг | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) |
| KR20180054635A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서 이환형 화합물 |
| CN115124538A (zh) | 2015-09-24 | 2022-09-30 | 豪夫迈·罗氏有限公司 | 作为atx抑制剂的二环化合物 |
| US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| JP7157755B2 (ja) | 2017-03-16 | 2022-10-20 | エフ．ホフマン－ラ ロシュ アーゲー | 二重ａｔｘ／ｃａ阻害剤として有用な複素環式化合物 |
| WO2019014322A1 (en) | 2017-07-11 | 2019-01-17 | BioAxone BioSciences, Inc. | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES |
| WO2022150676A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9000301D0 (en) * | 1990-01-06 | 1990-03-07 | Pfizer Ltd | Piperidine & pyrrolidine derivatives |
| GB9202443D0 (en) * | 1992-02-05 | 1992-03-18 | Fujisawa Pharmaceutical Co | A novel substituted-acetamide compound and a process for the preparation thereof |
| EP0747355A4 (en) * | 1994-02-10 | 1997-04-09 | Yamanouchi Pharma Co Ltd | NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM |
| JPH07258250A (ja) * | 1994-03-25 | 1995-10-09 | Yamanouchi Pharmaceut Co Ltd | エステル誘導体 |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| JPH08291141A (ja) * | 1995-04-21 | 1996-11-05 | Kotobuki Seiyaku Kk | ジフェニル酢酸誘導体及びその製造法 |
| JPH09278749A (ja) * | 1996-04-10 | 1997-10-28 | Taisho Pharmaceut Co Ltd | 複素環誘導体 |
| JPH09278751A (ja) * | 1996-04-12 | 1997-10-28 | Taisho Pharmaceut Co Ltd | ピペラジン誘導体 |
-
1999
- 1999-02-03 WO PCT/JP1999/000462 patent/WO1999040070A1/ja not_active Ceased
- 1999-02-03 HU HU0102404A patent/HUP0102404A2/hu unknown
- 1999-02-03 JP JP2000530500A patent/JP3613179B2/ja not_active Expired - Fee Related
- 1999-02-03 CA CA002317444A patent/CA2317444C/en not_active Expired - Fee Related
- 1999-02-03 KR KR1020007008571A patent/KR20010040693A/ko not_active Withdrawn
- 1999-02-03 DE DE69922494T patent/DE69922494T2/de not_active Expired - Lifetime
- 1999-02-03 EP EP99902825A patent/EP1061076B1/en not_active Expired - Lifetime
- 1999-02-03 IL IL13716699A patent/IL137166A0/xx unknown
- 1999-02-03 CN CN99802687A patent/CN1290251A/zh active Pending
- 1999-02-03 AT AT99902825T patent/ATE284389T1/de not_active IP Right Cessation
- 1999-02-03 HR HR20000495A patent/HRP20000495B1/xx not_active IP Right Cessation
- 1999-02-03 AU AU22986/99A patent/AU745995B2/en not_active Ceased
- 1999-02-03 TR TR2000/02241T patent/TR200002241T2/xx unknown
- 1999-02-03 SK SK1140-2000A patent/SK11402000A3/sk unknown
- 1999-02-03 PL PL99342735A patent/PL342735A1/xx unknown
- 1999-02-03 EE EEP200000458A patent/EE200000458A/xx unknown
- 1999-02-03 YU YU41100A patent/YU41100A/sh unknown
- 1999-02-03 AR ARP990100449A patent/AR015512A1/es unknown
- 1999-02-03 BR BR9908351-5A patent/BR9908351A/pt not_active Application Discontinuation
- 1999-02-03 ES ES99902825T patent/ES2235458T3/es not_active Expired - Lifetime
- 1999-02-04 PE PE1999000093A patent/PE20000263A1/es not_active Application Discontinuation
- 1999-02-04 US US09/244,985 patent/US6140333A/en not_active Expired - Fee Related
-
2000
- 2000-08-02 IS IS5580A patent/IS5580A/is unknown
- 2000-08-04 BG BG104663A patent/BG104663A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK11402000A3 (sk) | 2001-03-12 |
| ATE284389T1 (de) | 2004-12-15 |
| JP3613179B2 (ja) | 2005-01-26 |
| WO1999040070A1 (en) | 1999-08-12 |
| EE200000458A (et) | 2002-02-15 |
| HUP0102404A2 (hu) | 2001-11-28 |
| ES2235458T3 (es) | 2005-07-01 |
| EP1061076A1 (en) | 2000-12-20 |
| DE69922494D1 (de) | 2005-01-13 |
| PE20000263A1 (es) | 2000-04-25 |
| HRP20000495B1 (en) | 2005-12-31 |
| CN1290251A (zh) | 2001-04-04 |
| CA2317444A1 (en) | 1999-08-12 |
| EP1061076B1 (en) | 2004-12-08 |
| KR20010040693A (ko) | 2001-05-15 |
| BR9908351A (pt) | 2001-11-20 |
| TR200002241T2 (tr) | 2000-11-21 |
| DE69922494T2 (de) | 2005-05-25 |
| AR015512A1 (es) | 2001-05-02 |
| CA2317444C (en) | 2008-12-02 |
| US6140333A (en) | 2000-10-31 |
| HRP20000495A2 (en) | 2003-06-30 |
| PL342735A1 (en) | 2001-07-02 |
| IS5580A (is) | 2000-08-02 |
| BG104663A (en) | 2001-09-28 |
| IL137166A0 (en) | 2001-07-24 |
| EP1061076A4 (en) | 2001-05-02 |
| AU745995B2 (en) | 2002-04-11 |
| AU2298699A (en) | 1999-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU41100A (sh) | N-acil derivati cikličnih amina | |
| IL93257A0 (en) | Nitrogen containing heterocyclic derivatives,their preparation and pharmaceutical compositions containing them | |
| YU1299A (sh) | 1,4-disupstituisani derivati piperidina koji sadrže fluor | |
| HU9502512D0 (en) | Anthranilic acid derivative | |
| GB0001930D0 (en) | Organic compounds | |
| PL275423A1 (en) | Method of obtaining novel heterocyclic compounds | |
| HUT48250A (en) | Process for producing new benzimidazolin-2-oxo-1-carboxylic acid derivatives of 5-ht receptor antagonistic activity and pharmaceutical compositions containing them | |
| DE69428206D1 (de) | Chinolincarbonsäurederivate und ihre salze | |
| ES2111326T3 (es) | Derivados de imidazolona y oxazolona como antagonistas de dopamina. | |
| ES2174077T3 (es) | Derivados de hidroxilamina antiisquemicos y composiciones farmaceuticas. | |
| ATE245155T1 (de) | N-substituierte 1-(butyrolacton)-isochinoline zur behandlung von nervenstörungen | |
| SE8702697D0 (sv) | Method of treating ischaemic vascular diseases | |
| WO2001029017A3 (fr) | 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES ET 1,4-THIOBUTYROLACTONES N-SUBSTITUEES UTILES COMME STIMULANT DE L'ACTIVITE DE L'ACIDE η-AMINOBUTYRIQUE ET DANS LE TRAITEMENT DES TROUBLES NERVEUX ET LEUR PROCEDE DE PREPARATION |